Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
KLK10
REST API REST API
Homo sapiens
KLK10 is differentially expressed in 223 experiments: 141 organism parts: lung, tonsil, ... (139 more);, 139 disease states: normal, colorectal adenocarcinoma, ... (137 more);, 58 cell types 444 cell lines 28 compound treatments and 62 other conditions.
Synonyms PRSSL1, NES1
Orthologs Q0VCZ4_BOVIN (Bos taurus)   Klk10 (Mus musculus)   Klk10 (Rattus norvegicus)   KLK10 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term peptidase activity, extracellular region, cell cycle, serine-type peptidase activity, proteolysis, serine-type endopeptidase activity
InterPro Term Peptidase_S1A, Peptidase_S1_S6
UniProt Accession O43240
Search EB-eye ENSG00000129451
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-MEXP-1251, ... (22 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, E-GEOD-18005, ... (28 experiments)

Factor Value U/D Experiments
SW480
4
E-MTAB-37, E-MEXP-1014, E-GEOD-2509, E-GEOD-18005
MCF-7
3
E-GEOD-5823, E-GEOD-19639, E-GEOD-20081
AGS
2
E-MTAB-37, E-GEOD-15460
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
HCC1143
2
E-MTAB-37, E-MTAB-62
HCC1937
2
E-MTAB-37, E-MTAB-62
438 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-19397, E-GEOD-3920, E-MEXP-66, E-GEOD-4219, ... (33 experiments)

Factor Value U/D Experiments
CD8+ T cell
3
E-AFMX-5, E-MTAB-25, E-GEOD-6740
human embryonic stem cell
3
E-GEOD-20033, E-GEOD-18147, E-GEOD-18265
2
E-TABM-145, E-TABM-130
leydig cell
1
E-MTAB-25
naive T cell
1
E-GEOD-1460
neutrophil
1
E-GEOD-12662
52 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-2466, E-GEOD-3678, E-GEOD-5370, E-MTAB-62, ... (50 experiments)

Factor Value U/D Experiments
gastric carcinoma
2
E-GEOD-15460, E-MTAB-37
astrocytoma
2
E-MTAB-37, E-MTAB-62
acute lymphoblastic leukemia
2
E-MTAB-62, E-MTAB-37
adenocarcinoma
2
E-MTAB-37, E-MTAB-62
lung adenocarcinoma
2
E-GEOD-2514, E-MTAB-62
colorectal adenocarcinoma
1
2
E-AFMX-5, E-MTAB-62, E-TABM-145
133 more value(s).


Compound treatment

studied in E-GEOD-1615, E-GEOD-7400, E-GEOD-5824, E-GEOD-5099, E-GEOD-6462, ... (18 experiments)

Factor Value U/D Experiments
none
2
3
E-GEOD-20719, E-GEOD-412, E-GEOD-5824, E-GEOD-1615, E-GEOD-7400 ... (5 experiments)
dimethyl sulfoxide
1
E-GEOD-6932
17beta-estradiol
4
1
E-GEOD-2292
valproic acid
1
E-GEOD-1615
not specified
1
E-GEOD-20081
control - keratinocyte growth factor
1
E-GEOD-7216
22 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-GEOD-19743, E-GEOD-2171, E-GEOD-21589, E-GEOD-16363

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-GEOD-22513, ... (8 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, E-GEOD-4667, ... (7 experiments)

Dfs follow up
studied in E-GEOD-22541

dfs time (months)
studied in E-GEOD-21653

Disease free interval dfi in months
studied in E-GEOD-22541

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-3325, E-GEOD-2509, E-TABM-147, ... (6 experiments)

Environmental stress
studied in E-GEOD-1643

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-7578

Genotype
studied in E-MEXP-1996, E-GEOD-2466, E-GEOD-17476, E-GEOD-21750, E-TABM-321, ... (9 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-20540, E-MEXP-1446

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-302

Individual
studied in E-GEOD-1926, E-TABM-666, E-GEOD-19330, E-GEOD-19519, E-GEOD-6919, ... (23 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-9723, E-MEXP-561 ... (5 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-GEOD-2004, E-LGCL-5

Phenotype
studied in E-GEOD-1309, E-GEOD-21750, E-GEOD-7114

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

Replicate
studied in E-GEOD-10797

RNAi
studied in E-MEXP-1509, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, E-MEXP-2759 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-GEOD-17400

Sex
studied in E-GEOD-2466, E-GEOD-7307

Strain or line
studied in E-MEXP-1996

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-19246

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-1561

Tumor size
studied in E-GEOD-6532

Processing time: 0.405 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM